CATTANEO, DANIELE
CATTANEO, DANIELE
Dipartimento di Oncologia ed Emato-Oncologia
Unravelling a clinical role of peripheral blood leukemia stem cells at diagnosis in chronic myeloid leukemia patients: Final results of prospective FLOWERS study
2025 A. Sicuranza, P. Pacelli, A. Santoni, E. Abruzzese, D. Cattaneo, A. Iurlo, L. Luciano, S. Galimberti, V. Giai, O. Mulas, G. Caocci, F. Sorà, I. Capodanno, M. Crugnola, A. Gozzini, S. Russo, M. Annunziata, C. Fozza, A. Cartocci, S. Fredducci, E. Pacini, A.M. Liberati, M. Defina, E. Bestoso, C. Marzano, D. Tocci, T. Miracapillo, C. Turriziani, K. Peccia, D. Raspadori, M. Bocchia
Atypical chronic myeloid leukemia: From diagnosis to molecular features and therapeutic options
2025 A. Iurlo, D. Cattaneo, U. Gianelli, F. Passamonti
Reply to: Association between nilotinib-induced hyperbilirubinemia and UGT1A1 polymorphisms in a chronic myeloid leukemia patient
2025 D. Cattaneo, A. Iurlo
Bosutinib Treatment of Chronic Myeloid Leukemia in Lombardy
2025 A. Iurlo, C. Bucelli, T. Intermesoli, C. Elena, M. D'Adda, E. Agostani, C. Fiamenghi, M. Maffioli, N. Orofino, F. Lunghi, A. Gardellini, M.C. Carraro, A. Inzoli, F. Gigli, R. Palazzolo, V. Bertolli, D. Cattaneo, E.M. Pungolino, C. Gambacorti-Passerini
Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design
2025 V. De Stefano, F. Passamonti, F. Palandri, F. Ramundo, E. Rossi, S. Betti, L. Fagiolo, P. Guglielmelli, D.P. Abagnale, N. Pugliese, D. Cattaneo, A. Iurlo, F. Branzanti, A. Dedola, H. Catellani, A. Tieghi, M. Basso, E. Calistri, E.M. Elli, E. Masselli, E. Morsia, G. Benevolo, M. Breccia, V. De Fazio, M. Di Perna, M. Marchetti, M. Santoro, A. Tafuri, C. Castiglioni, C. Rotella, S. Siragusa, A.M. Vannucchi, N. Null
Neutrophil-to-Lymphocyte ratio as surrogate for JAK2V617F suppression and event-free survival in polycythemia vera
2025 T. Barbui, A. Ghirardi, V. Empson, F. Fenili, G.G. Loscocco, A. Condorelli, A. Iurlo, D. Cattaneo, E. Rossi, V. De Stefano, P. Guglielmelli, C. Klade, H. Gisslinger, A. Rambaldi, J.M. Scandura, A.M. Vannucchi
Circulating Levels of PF4/CXCL4 in Patients With BCR::ABL1-Negative Myeloproliferative Neoplasms: A New Potential Prognostic Factor for Disease Progression
2025 V. Bellani, D. Cattaneo, V. Abbonante, C. Bucelli, S. Stella, B. Mora, A. Malara, U. Gianelli, A. Balduini, A. Iurlo
SETD2 loss of function is a recurrent event in advanced‐phase chronic myeloid leukemia and contributes to genomic instability
2025 M. Mancini, S. De Santis, C. Monaldi, F. Castagnetti, M. Iezza, A. Iurlo, D. Cattaneo, S. Galimberti, M. Cerrano, I. Capodanno, M. Bonifacio, M. Rossi, C. Agostinelli, M. Meggendorfer, T. Haferlach, M. Cavo, G. Gugliotta, S. Soverini
The 2024 Three‐Strata Baseline Anemia Definition of the Revised IWG‐ELN Criteria Dissects Survival in Ruxolitinib‐Treated Myelofibrosis Patients
2025 M. Maffioli, B. Mora, A. Iurlo, E.M. Elli, M.C. Finazzi, M. Farina, E. Rumi, M. Caramella, M.C. Carraro, M. D'Adda, A. Molteni, E. Mimiola, F. Lunghi, A. Vismara, M. Ubezio, M.C. Di Chio, M. Anghilieri, D. Cattaneo, M.G. Della Porta, L. Bertù, M. Coscia, F. Passamonti
Value and limitations of targeted next-generation sequencing in idiopathic hypereosinophilia: an integrative diagnostic tool in challenging cases
2024 D. Cattaneo, A. Marchetti, C. Bucelli, N. Galli, M. Lionetti, V. Bellani, U. Gianelli, F. Passamonti, N. Bolli, A. Iurlo
Treatment‐free remission as a new goal in the management of chronic myeloid leukemia: Clinical and biological aspects
2024 D. Cattaneo, C. Bucelli, V. Bellani, B. Mora, A. Iurlo
Red cell distribution width and prognosis in myelofibrosis patients treated with ruxolitinib
2024 D. Cattaneo, N. Galli, C. Bucelli, C.A. Fidanza, V. Bellani, S. Artuso, P. Bianchi, D. Consonni, F. Passamonti, A. Iurlo
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib
2024 O. Mulas, E. Abruzzese, L. Luciano, A. Iurlo, I. Attolico, F. Castagnetti, S. Galimberti, M. Bonifacio, M. Annunziata, A. Gozzini, E.M. Orlandi, F. Stagno, G. Binotto, P. Pregno, C. Fozza, M. Loi, M.M. Trawinska, F. De Gregorio, D. Cattaneo, F. Albano, M. Iezza, C. Baratè, L. Scaffidi, C. Elena, V. Giai, E. Scalzulli, M. Breccia, G. La Nasa, G. Caocci
Prognostic and Predictive Models in Myelofibrosis
2024 B. Mora, C. Bucelli, D. Cattaneo, V. Bellani, F. Versino, K. Barbullushi, N. Fracchiolla, A. Iurlo, F. Passamonti
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes
2024 T. Barbui, A. Carobbio, V. De Stefano, A. Alvarez-Larran, A. Ghirardi, G. Carioli, F. Fenili, E. Rossi, F. Ciceri, M. Bonifacio, A. Iurlo, F. Palandri, G. Benevolo, F. Pane, A. Ricco, G. Carli, M. Caramella, D. Rapezzi, C. Musolino, S. Siragusa, E. Rumi, A. Patriarca, N. Cascavilla, B. Mora, E. Cacciola, L. Calabresi, G.G. Loscocco, P. Guglielmelli, F. Gesullo, S. Betti, F. Ramundo, F. Lunghi, L. Scaffidi, C. Bucelli, D. Cattaneo, N. Vianelli, M. Bellini, M.C. Finazzi, G. Tognoni, A. Rambaldi, A.M. Vannucchi
Newly identified roles for PIEZO1 mechanosensor in controlling normal megakaryocyte development and in primary myelofibrosis
2024 V. Abbonante, A.I. Karkempetzaki, C. Leon, A. Krishnan, N. Huang, C.A. Di Buduo, D. Cattaneo, C.M. Ward, S. Matsuura, I. Guinard, J. Weber, A. De Acutis, G. Vozzi, A. Iurlo, K. Ravid, A. Balduini
Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trial
2024 B. Rocca, A. Tosetto, G. Petrucci, E. Rossi, S. Betti, D. Soldati, A. Iurlo, D. Cattaneo, C. Bucelli, A. Dragani, M. Di Ianni, P. Ranalli, F. Palandri, N. Vianelli, E. Beggiato, G. Lanzarone, M. Ruggeri, G. Carli, E.M. Elli, R. Renso, M.L. Randi, I. Bertozzi, G.G. Loscocco, A. Ricco, G. Specchia, A.M. Vannucchi, F. Rodeghiero, V. De Stefano, C. Patrono
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy
2024 F. Palandri, G.A. Palumbo, G. Benevolo, A. Iurlo, E.M. Elli, E. Abruzzese, N. Polverelli, M. Tiribelli, G. Auteri, A. Tieghi, G. Caocci, G. Binotto, F. Cavazzini, F. Branzanti, E. Beggiato, M. Miglino, C. Bosi, M. Crugnola, M. Bocchia, B. Martino, N. Pugliese, L. Scaffidi, M. Venturi, A. Duminuco, A. Isidori, D. Cattaneo, M. Krampera, F. Pane, D. Cilloni, G. Semenzato, R.M. Lemoli, A. Cuneo, M.M. Trawinska, N. Vianelli, M. Cavo, M. Bonifacio, M. Breccia
Neutrophilic and eosinophilic dermatoses associated with hematological malignancy
2024 C.A. Maronese, F. Derlino, C. Moltrasio, D. Cattaneo, A. Iurlo, A.V. Marzano
The molecular landscape of myeloproliferative neoplasms associated with splanchnic vein thrombosis: Current perspective
2024 C. Pescia, G. Lopez, D. Cattaneo, C. Bucelli, U. Gianelli, A. Iurlo